VRTX Vertex Pharmaceuticals Inc
Company Analysis
Latest News
Vertex Pharmaceuticals to Acquire Crinetics for $10 Billion in Rare Disease Push
Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals for approximately $10 billion in equity value, paying $85 per share in cash. [2, 3, 4]...
🟢 VRTX extends move to 5.1% up
VRTX is trading at $523.24, up 5.1% versus the comparison close of $498.01 during regular trading. This is a price-movement alert; no separate company-specific...
Vertex Expands Casgevy Approval to Young Children, Reaching 5,500 New Patients
Vertex Pharmaceuticals received FDA approval to expand the use of its gene therapy, Casgevy, to children aged 2 to 11. This one-time treatment targets patients...
🟢 VRTX is trading 4.5% up today as it breaks above key resistance
VRTX is trading 4.5% up at $501.91 as the stock extends a multi-day rebound and breaks above recent resistance near $483. • The move continues a strong...
Vertex Pharmaceuticals misses first quarter 2026 revenue estimates but beats on EPS as new product diversification begins to take hold.
Vertex Pharmaceuticals reported first quarter 2026 revenue of $2.99 billion, an 8% increase year-over-year, and non-GAAP diluted EPS of $4.47. These results...
Vertex Pharmaceuticals Inc Q1 2026 Earnings Preview: What Analysts Expect on May 04, 2026
Vertex Pharmaceuticals is expected to report consensus revenue of $3.25 billion and EPS of $3.67, with the current stock price of $448.20 trading below the...